News and Trends 17 Jul 2017 A Brand New Outlook on Induced Pluripotent Stem Cells …dead. Cells from patients suffering from Alzheimer’s disease can be reprogrammed and used to understand the differences between healthy cells and those affected by the disease In the broader field… July 17, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Dec 2023 Seven companies shaping the future of precision medicine …designed to bind to the tau protein, which is linked to Alzheimer’s disease progression. The multi-million dollar company has numerous candidates undergoing phase 2 studies. This includes the Abeta vaccine,… December 14, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 26 Sep 2024 The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond …making their way into neurodegenerative diseases diagnostic. “We are excited about the promise radiopharmaceuticals are showing in neurology, particularly Alzheimer’s disease which has long lacked effective diagnostics,” said Markison. Artificial… September 26, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 8 Nov 2017 Interviewing Europe’s Most Intense Investor about Trends in Biotech I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday… November 8, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland …company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. Located in Switzerland,… December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval …neurodegenerative disease has been booming but not without disappointments like the failures of Eli Lilly and then Merck in Alzheimer’s Disease. While Alzheimer’s has been the focus of these efforts,… May 12, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jan 2025 A surge in deals: GSK bets on ADC, neuro and fibrotic diseases to bolster drug development …with Danish startup Muna Therapeutics to develop treatments for Alzheimer’s disease. The €33.5 million ($35.14 million) deal will grant the pair the opportunity to validate novel drug targets and explore… January 2, 2025 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jan 2017 Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities Researchers from the UK have described a new treatment for cavities that could get rid of fillings and cements by employing an Alzheimer’s drug. Most of us have visited the… January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2017 What Could RNA Therapies Do for the Treatment of CNS Disorders? …are often met with skepticism, and De Vlaam didn’t expect the enthusiasm and excitement following the spin-out but he found it “exhilarating”. Despite Alzheimer’s being one of the obvious targets… October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 …should follow in clinical development. Serious Hope for Alzheimer’s This German biotech is trying to tackle Alzheimer’s, the disease that has probably led to the most clinical failures, as exemplified… January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2018 Celgene Partners With German Biotech to Develop Oncology Treatments …after a previous €43M ($45M) deal focusing on Alzheimer’s achieved its first milestone in October of last year. The company has been successful at signing deals with other big industry… May 22, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 …Auvelity, Axsome has seen a promising phase 3 readout for a candidate treatment for agitation in Alzheimer’s disease. In 2023, Axsome is also expected to report phase 3 results for… December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email